RNA-sequence-based microRNA expression signature in breast cancer: tumor-suppressive miR-101-5p regulates molecular

Hiroko Toda1, Naohiko Seki2, Sasagu Kurozumi3

  • 1Department of Digestive Surgery, Breast and Thyroid Surgery, Graduate School of Medical and Dental Sciences, Kagoshima University, Japan.

Molecular Oncology
|November 23, 2019
PubMed

Insights

This study identified tumor-suppressive microRNAs (miRNAs) in breast cancer (BrCa), finding that low miR-101-5p expression predicts poor prognosis. Restoring miR-101-5p inhibits BrCa cell aggressiveness and identifies oncogenic targets like GINS1, offering new therapeutic strategies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Aberrant microRNA (miRNA) expression disrupts cellular RNA networks in cancer.
  • Understanding miRNA-dependent molecular networks is crucial for cancer research.

Purpose of the Study:

  • To identify tumor-suppressive miRNAs in breast cancer (BrCa).
  • To investigate the role of miR-101-5p and its targets in BrCa pathogenesis.
  • To explore the oncogenic function of GINS1 in BrCa.

Main Methods:

  • RNA-sequencing of BrCa clinical specimens.
  • Analysis of miRNA expression and patient prognosis.
  • Functional assays (ectopic expression, knockdown) in BrCa cells.
  • Identification of miRNA targets using bioinformatics and experimental validation.

Main Results:

  • 64 candidate tumor-suppressive miRNAs were identified in BrCa.
  • Downregulation of several miRNA duplexes, including miR-101-5p, was observed in BrCa tissues.
  • Low miR-101-5p expression correlated with poor BrCa patient survival.
  • Ectopic miR-101-5p expression suppressed BrCa cell proliferation, migration, and invasion.
  • Seven oncogenic targets regulated by miR-101-5p were identified, including GINS1.
  • High GINS1 expression predicted poor BrCa prognosis and its knockdown inhibited malignant phenotypes.

Conclusions:

  • miR-101-5p acts as a tumor suppressor in BrCa by targeting oncogenic genes like GINS1.
  • GINS1 is an oncogene in BrCa, promoting malignant phenotypes.
  • Identifying miRNA-driven molecular networks is a promising strategy for understanding BrCa pathogenesis and developing therapies.

Related Concept Videos

MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.7K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
23.8K
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
9.7K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.6K
Experimental RNAi02:15

Experimental RNAi

RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
7.2K